Ultimovacs, a clinical-stage biotechnology company, has announced data from the Phase II NIPU trial results of the UV1 cancer vaccine. 

The investigator-initiated, open-label, multi-center Phase II trial NIPU assessed the effect of adding the cancer vaccine to second-line treatment with ipilimumab and nivolumab for pleural mesothelioma patients. 

Malignant pleural mesothelioma is an aggressive type of cancer. It occurs in the thin layer of tissue that surrounds the lungs and inside part of the chest. 

Sponsored by Oslo University Hospital and supported by Bristol-Myers Squibb and Ultimovacs, the NIPU trial involved six university hospitals across Denmark, Australia, Norway, Spain, and Sweden.  

From June 2020 to January 2023, a total of 118 patients were randomised as part of the trial. 

The NIPU trial’s objective was to achieve a clinically meaningful PFS benefit in patients with malignant pleural mesothelioma (MPM) after first-line chemotherapy. The combination of ipilimumab and nivolumab has been approved as a first-line treatment in the US and Europe. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

While the primary endpoint of improved progression-free survival (PFS) was not met, secondary endpoints showed a significant benefit, the company said. 

The objective response rate (ORR) and overall survival (OS) were positively impacted by adding UV1 to the treatment regimen.  

Notably, patients with the epithelioid subtype of mesothelioma, which accounts for about 70% of cases, demonstrated further improvement. 

In a press statement, Ultimovacs said: “The safety profile of the combination of UV1 plus ipilimumab and nivolumab observed in the trial was consistent with that of ipilimumab and nivolumab alone, confirming the good safety profile for the UV1 vaccine.”